ABEONA THERAPEUTICS INC. Impairment of Intangible Assets, Finite-lived
ABEONA THERAPEUTICS INC. (ABEO) reported Impairment of Intangible Assets, Finite-lived of $1.40 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2022-11-14
- ABEONA THERAPEUTICS INC. impairment of intangible assets, finite-lived for the quarter ending 2022-09-30 was $0.00.
- ABEONA THERAPEUTICS INC. impairment of intangible assets, finite-lived for the quarter ending 2022-06-30 was $45.00K.
- ABEONA THERAPEUTICS INC. impairment of intangible assets, finite-lived for the quarter ending 2022-03-31 was $1.35M.
- ABEONA THERAPEUTICS INC. impairment of intangible assets, finite-lived for fiscal 2016 was $0.00.
- ABEONA THERAPEUTICS INC. impairment of intangible assets, finite-lived for fiscal 2015 was $0.00.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $45.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.40M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.40M 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | $1.35M 10-Q · filed 2022-05-13 | |||
| 2016-12-31 | $0.00 10-K · filed 2017-03-30 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |